VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q53341545 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241120235805.0
008 241120nneanz||abbn n and d
035 ‎‡a (WKP)Q53341545‏
024 ‎‡a 0000-0002-7119-2244‏ ‎‡2 orcid‏
024 ‎‡a 18342739200‏ ‎‡2 scopus‏
024 ‎‡a 7201394105‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q53341545‏
100 0 ‎‡a María T Serrano‏ ‎‡9 ast‏ ‎‡9 es‏ ‎‡9 sl‏
375 ‎‡a 2‏ ‎‡2 iso5218‏
400 0 ‎‡a María T Serrano‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a María T Serrano‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.‏
670 ‎‡a Author's Acute necrotizing pancreatitis and severe hepatic failure: description of three cases.‏
670 ‎‡a Author's Angiogenesis and proliferation markers in adjacent cirrhotic tissue could predict hepatocellular carcinoma outcome after liver transplantation‏
670 ‎‡a Author's Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil.‏
670 ‎‡a Author's CD24 Expression Is Increased in 5-Fluorouracil-Treated Esophageal Adenocarcinoma Cells.‏
670 ‎‡a Author's Celsior versus University of Wisconsin preserving solutions for liver transplantation: postreperfusion syndrome and outcome of a 5-year prospective randomized controlled study.‏
670 ‎‡a Author's Control of blood pressure in liver transplant recipients.‏
670 ‎‡a Author's Controlling Diabetes After Liver Transplantation: Room for Improvement‏
670 ‎‡a Author's Effect of Dimethyl Sulfoxide and Melatonin on the Isolation of Human Primary Hepatocytes.‏
670 ‎‡a Author's Evaluation of Institut Georges Lopez-1 preservation solution in pig pancreas transplantation: a pilot study.‏
670 ‎‡a Author's Graft survival after liver transplantation: an approach to a new Spanish risk index‏
670 ‎‡a Author's How important is donor age in liver transplantation?‏
670 ‎‡a Author's Human immunodeficiency virus-infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study‏
670 ‎‡a Author's Immunosuppression in liver transplantation: renoprotective regimens‏
670 ‎‡a Author's Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients.‏
670 ‎‡a Author's Incubation with dimethyl sulfoxide prior to cryopreservation improves functionality of thawed human primary hepatocytes‏
670 ‎‡a Author's Intention-to-treat survival analysis of hepatitis C virus/human immunodeficiency virus coinfected liver transplant: Is it the waiting list?‏
670 ‎‡a Author's Liver transplant, in emergency 0 (UNOS Status 1).‏
670 ‎‡a Author's Liver transplanted patients with donors older than 60 years require more hospital resources‏
670 ‎‡a Author's Multiple approaches to assess fourteen non-invasive serum indexes for the diagnosis of liver fibrosis in chronic hepatitis C patients‏
670 ‎‡a Author's Naturally-Derived Biomaterials for Tissue Engineering Applications‏
670 ‎‡a Author's Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib.‏
670 ‎‡a Author's [Orthotopic liver transplantation for giant polycystic disease of the liver with terminal liver failure]‏
670 ‎‡a Author's Outcome of liver transplantation using donors older than 60 years of age‏
670 ‎‡a Author's Preservation of the liver graft with Celsior solution‏
670 ‎‡a Author's Prevalence and progression of chronic kidney disease after liver transplant: a prospective, real-life, observational, two-year multicenter study‏
670 ‎‡a Author's Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain‏
670 ‎‡a Author's Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.‏
670 ‎‡a Author's The role of extracellular matrix on liver stem cell fate: A dynamic relationship in health and disease‏
670 ‎‡a Author's [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].‏
670 ‎‡a Author's Treatment of Cutaneous Infection by Alternaria alternata With Voriconazole in a Liver Transplant Patient‏
670 ‎‡a Author's Viral hepatitis: A health problem that requires appropriate planning.‏
909 ‎‡a (scopus) 7201394105‏ ‎‡9 1‏
909 ‎‡a (scopus) 18342739200‏ ‎‡9 1‏
909 ‎‡a (orcid) 0000000271192244‏ ‎‡9 1‏
919 ‎‡a cardiovascularmorbidityandmortalityafterlivertransplantationtheprotectiveroleofmycophenolatemofetil‏ ‎‡A Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil.‏ ‎‡9 1‏
919 ‎‡a cd24expressionisincreasedin5fluorouraciltreatedesophagealadenocarcinomacells‏ ‎‡A CD24 Expression Is Increased in 5-Fluorouracil-Treated Esophageal Adenocarcinoma Cells.‏ ‎‡9 1‏
919 ‎‡a celsiorversusuniversityofwisconsinpreservingsolutionsforlivertransplantationpostreperfusionsyndromeandoutcomeofa5yearprospectiverandomizedcontrolledstudy‏ ‎‡A Celsior versus University of Wisconsin preserving solutions for liver transplantation: postreperfusion syndrome and outcome of a 5-year prospective randomized controlled study.‏ ‎‡9 1‏
919 ‎‡a controlofbloodpressureinlivertransplantrecipients‏ ‎‡A Control of blood pressure in liver transplant recipients.‏ ‎‡9 1‏
919 ‎‡a controllingdiabetesafterlivertransplantationroomforimprovement‏ ‎‡A Controlling Diabetes After Liver Transplantation: Room for Improvement‏ ‎‡9 1‏
919 ‎‡a effectofdimethylsulfoxideandmelatoninontheisolationofhumanprimaryhepatocytes‏ ‎‡A Effect of Dimethyl Sulfoxide and Melatonin on the Isolation of Human Primary Hepatocytes.‏ ‎‡9 1‏
919 ‎‡a evaluationofinstitutgeorgeslopez1preservationsolutioninpigpancreastransplantationapilotstudy‏ ‎‡A Evaluation of Institut Georges Lopez-1 preservation solution in pig pancreas transplantation: a pilot study.‏ ‎‡9 1‏
919 ‎‡a graftsurvivalafterlivertransplantationanapproachtoanewspanishriskindex‏ ‎‡A Graft survival after liver transplantation: an approach to a new Spanish risk index‏ ‎‡9 1‏
919 ‎‡a howimportantisdonorageinlivertransplantation‏ ‎‡A How important is donor age in liver transplantation?‏ ‎‡9 1‏
919 ‎‡a humanimmunodeficiencyvirusinfectedlivertransplantrecipientswithincidentalhepatocellularcarcinomaaprospectivemulticenternationwidecohortstudy‏ ‎‡A Human immunodeficiency virus-infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study‏ ‎‡9 1‏
919 ‎‡a immunosuppressioninlivertransplantationrenoprotectiveregimens‏ ‎‡A Immunosuppression in liver transplantation: renoprotective regimens‏ ‎‡9 1‏
919 ‎‡a impactoftacrolimusandmycophenolatemofetilregimenvsaconventionaltherapywithsteroidsoncardiovascularriskinlivertransplantpatients‏ ‎‡A Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients.‏ ‎‡9 1‏
919 ‎‡a incubationwithdimethylsulfoxidepriortocryopreservationimprovesfunctionalityofthawedhumanprimaryhepatocytes‏ ‎‡A Incubation with dimethyl sulfoxide prior to cryopreservation improves functionality of thawed human primary hepatocytes‏ ‎‡9 1‏
919 ‎‡a intentiontotreatsurvivalanalysisofhepatitis100virushumanimmunodeficiencyviruscoinfectedlivertransplantisitthewaitinglist‏ ‎‡A Intention-to-treat survival analysis of hepatitis C virus/human immunodeficiency virus coinfected liver transplant: Is it the waiting list?‏ ‎‡9 1‏
919 ‎‡a livertransplantinemergency0unosstatus1‏ ‎‡A Liver transplant, in emergency 0 (UNOS Status 1).‏ ‎‡9 1‏
919 ‎‡a livertransplantedpatientswithdonorsolderthan60yearsrequiremorehospitalresources‏ ‎‡A Liver transplanted patients with donors older than 60 years require more hospital resources‏ ‎‡9 1‏
919 ‎‡a multipleapproachestoassess14noninvasiveserumindexesforthediagnosisofliverfibrosisinchronichepatitis100patients‏ ‎‡A Multiple approaches to assess fourteen non-invasive serum indexes for the diagnosis of liver fibrosis in chronic hepatitis C patients‏ ‎‡9 1‏
919 ‎‡a naturallyderivedbiomaterialsfortissueengineeringapplications‏ ‎‡A Naturally-Derived Biomaterials for Tissue Engineering Applications‏ ‎‡9 1‏
919 ‎‡a angiogenesisandproliferationmarkersinadjacentcirrhotictissuecouldpredicthepatocellularcarcinomaoutcomeafterlivertransplantation‏ ‎‡A Angiogenesis and proliferation markers in adjacent cirrhotic tissue could predict hepatocellular carcinoma outcome after liver transplantation‏ ‎‡9 1‏
919 ‎‡a acutenecrotizingpancreatitisandseverehepaticfailuredescriptionof3cases‏ ‎‡A Acute necrotizing pancreatitis and severe hepatic failure: description of three cases.‏ ‎‡9 1‏
919 ‎‡a comparisonofsurvivalinpatientswithhepatocellularcarcinomaandportalveininvasiontreatedbyradioembolizationorsorafenib‏ ‎‡A A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.‏ ‎‡9 1‏
919 ‎‡a neutrophiltolymphocyteratiopredictssurvivalineuropeanpatientswithhepatocellularcarcinomaadministeredsorafenib‏ ‎‡A Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib.‏ ‎‡9 1‏
919 ‎‡a orthotopiclivertransplantationforgiantpolycysticdiseaseoftheliverwithterminalliverfailure‏ ‎‡A [Orthotopic liver transplantation for giant polycystic disease of the liver with terminal liver failure]‏ ‎‡9 1‏
919 ‎‡a outcomeoflivertransplantationusingdonorsolderthan60yearsofage‏ ‎‡A Outcome of liver transplantation using donors older than 60 years of age‏ ‎‡9 1‏
919 ‎‡a preservationofthelivergraftwithcelsiorsolution‏ ‎‡A Preservation of the liver graft with Celsior solution‏ ‎‡9 1‏
919 ‎‡a prevalenceandprogressionofchronickidneydiseaseafterlivertransplantaprospectivereallifeobservational2yearmulticenterstudy‏ ‎‡A Prevalence and progression of chronic kidney disease after liver transplant: a prospective, real-life, observational, two-year multicenter study‏ ‎‡9 1‏
919 ‎‡a renalfunctionimprovementinlivertransplantrecipientsafterearlyeverolimusconversionaclinicalpracticecohortstudyinspain‏ ‎‡A Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain‏ ‎‡9 1‏
919 ‎‡a roleofmtorinhibitorsforthecontrolofviralinfectioninsolidorgantransplantrecipients‏ ‎‡A Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.‏ ‎‡9 1‏
919 ‎‡a roleofextracellularmatrixonliverstemcellfateadynamicrelationshipinhealthanddisease‏ ‎‡A The role of extracellular matrix on liver stem cell fate: A dynamic relationship in health and disease‏ ‎‡9 1‏
919 ‎‡a therapeuticdecisionsinthetreatmentofhepatocellularcarcinomaandpatternsofsorafenibuseresultsoftheinternationalobservationalgideontrialinspain‏ ‎‡A [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].‏ ‎‡9 1‏
919 ‎‡a treatmentofcutaneousinfectionbyalternariaalternatawithvoriconazoleinalivertransplantpatient‏ ‎‡A Treatment of Cutaneous Infection by Alternaria alternata With Voriconazole in a Liver Transplant Patient‏ ‎‡9 1‏
919 ‎‡a viralhepatitisahealthproblemthatrequiresappropriateplanning‏ ‎‡A Viral hepatitis: A health problem that requires appropriate planning.‏ ‎‡9 1‏
946 ‎‡a a‏ ‎‡9 1‏
996 ‎‡2 BNF|17828398‏
996 ‎‡2 ISNI|0000000371327097‏
996 ‎‡2 LC|n 2011182121‏
996 ‎‡2 ISNI|0000000046224078‏
996 ‎‡2 LC|n 2009024283‏
996 ‎‡2 BNE|XX922193‏
996 ‎‡2 SUDOC|081378149‏
996 ‎‡2 LC|n 2022252621‏
996 ‎‡2 ISNI|0000000035763156‏
996 ‎‡2 LC|no 91017575‏
996 ‎‡2 BLBNB|000261573‏
996 ‎‡2 DNB|12815859X‏
996 ‎‡2 NTA|301855854‏
996 ‎‡2 LC|n 2019074233‏
996 ‎‡2 BNF|16966897‏
996 ‎‡2 ISNI|0000000041958312‏
996 ‎‡2 SUDOC|030492246‏
996 ‎‡2 SUDOC|029920884‏
996 ‎‡2 SUDOC|180179799‏
996 ‎‡2 RERO|A000148153‏
996 ‎‡2 DNB|1181875013‏
996 ‎‡2 LC|n 2017181754‏
996 ‎‡2 ISNI|000000043484974X‏
996 ‎‡2 BLBNB|000282785‏
996 ‎‡2 BNE|XX5110015‏
996 ‎‡2 LC|n 96028044‏
996 ‎‡2 LC|nb2020000883‏
996 ‎‡2 LC|nr 91002824‏
996 ‎‡2 DNB|1325655384‏
996 ‎‡2 BNE|XX1281977‏
996 ‎‡2 BNE|XX957764‏
996 ‎‡2 LC|n 87877167‏
996 ‎‡2 SUDOC|196783283‏
996 ‎‡2 BNE|XX5445966‏
996 ‎‡2 PTBNP|1430002‏
996 ‎‡2 RERO|A002955071‏
996 ‎‡2 SUDOC|144269996‏
996 ‎‡2 LC|no2002019393‏
996 ‎‡2 LC|no2001062368‏
996 ‎‡2 DNB|139123326‏
996 ‎‡2 BNF|17708890‏
996 ‎‡2 BNC|981058526950206706‏
996 ‎‡2 ISNI|0000000107188462‏
996 ‎‡2 ISNI|0000000069919235‏
996 ‎‡2 DNB|1153614820‏
996 ‎‡2 LC|n 85018894‏
996 ‎‡2 BNE|XX5489539‏
996 ‎‡2 ISNI|0000000093555232‏
996 ‎‡2 BNF|17956592‏
996 ‎‡2 BNE|XX4580721‏
996 ‎‡2 LC|n 88003661‏
996 ‎‡2 LC|n 2017026029‏
996 ‎‡2 PTBNP|1453881‏
996 ‎‡2 BNF|14556603‏
996 ‎‡2 BNE|XX1119434‏
996 ‎‡2 BNE|XX1038925‏
996 ‎‡2 BNC|981058511059906706‏
996 ‎‡2 NII|DA0687048X‏
996 ‎‡2 LC|no2017059671‏
996 ‎‡2 BNE|XX1767950‏
996 ‎‡2 BNF|10137412‏
996 ‎‡2 BIBSYS|98029062‏
996 ‎‡2 RERO|A005838778‏
996 ‎‡2 SUDOC|078644437‏
996 ‎‡2 PLWABN|9810626268505606‏
996 ‎‡2 ISNI|0000000107358708‏
996 ‎‡2 CAOONL|ncf10711158‏
996 ‎‡2 BNE|XX5469155‏
996 ‎‡2 NUKAT|n 98040238‏
996 ‎‡2 DNB|140230602‏
996 ‎‡2 PTBNP|1737109‏
996 ‎‡2 BNE|XX6375456‏
996 ‎‡2 BNE|XX5634995‏
996 ‎‡2 SUDOC|08797956X‏
996 ‎‡2 BNE|XX1075523‏
996 ‎‡2 LC|no2016157089‏
996 ‎‡2 PLWABN|9812484101905606‏
996 ‎‡2 SUDOC|033184615‏
996 ‎‡2 LC|n 93065300‏
996 ‎‡2 LC|no2018104874‏
996 ‎‡2 LC|nb2016008039‏
996 ‎‡2 LC|n 97081990‏
996 ‎‡2 BNF|16536544‏
996 ‎‡2 BNC|981058597700606706‏
996 ‎‡2 LC|n 82223445‏
996 ‎‡2 NII|DA15449781‏
996 ‎‡2 BNE|XX929536‏
996 ‎‡2 DNB|1074954955‏
996 ‎‡2 NII|DA07722284‏
996 ‎‡2 ISNI|0000000081319785‏
996 ‎‡2 PLWABN|9810680486705606‏
996 ‎‡2 DNB|1157238270‏
996 ‎‡2 ISNI|0000000123466274‏
996 ‎‡2 ISNI|000000002415702X‏
996 ‎‡2 BNF|16271835‏
996 ‎‡2 SUDOC|172241251‏
996 ‎‡2 ISNI|0000000384966023‏
996 ‎‡2 BNE|XX6471179‏
996 ‎‡2 J9U|987007440804705171‏
996 ‎‡2 RERO|A003823010‏
996 ‎‡2 ARBABN|000058620‏
996 ‎‡2 ISNI|0000000443919359‏
996 ‎‡2 PLWABN|9812830165305606‏
996 ‎‡2 LC|n 97112624‏
996 ‎‡2 BNC|981058612085806706‏
996 ‎‡2 BNCHL|10000000000000000216269‏
996 ‎‡2 BNE|XX938004‏
996 ‎‡2 BNF|12189587‏
996 ‎‡2 DNB|1074669258‏
996 ‎‡2 BNE|XX5132226‏
996 ‎‡2 NTA|133221741‏
996 ‎‡2 BNE|XX4420696‏
996 ‎‡2 LC|nr 95015856‏
996 ‎‡2 LNB|LNC10-000308612‏
996 ‎‡2 LC|n 86052652‏
996 ‎‡2 LNB|LNC10-000308610‏
996 ‎‡2 BNF|12407681‏
996 ‎‡2 DNB|138579369‏
996 ‎‡2 J9U|987007404344705171‏
996 ‎‡2 JPG|500683824‏
996 ‎‡2 BNE|XX4948523‏
996 ‎‡2 BNC|981058613982606706‏
996 ‎‡2 CAOONL|ncf11595419‏
996 ‎‡2 BNE|XX5740265‏
996 ‎‡2 SUDOC|067005926‏
996 ‎‡2 ISNI|0000000059237943‏
996 ‎‡2 BNCHL|10000000000000000139158‏
996 ‎‡2 ISNI|0000000059715255‏
996 ‎‡2 ISNI|0000000373753970‏
996 ‎‡2 LC|no 00064533‏
996 ‎‡2 BNE|XX935037‏
996 ‎‡2 LC|nb2002015795‏
996 ‎‡2 LC|n 83049459‏
996 ‎‡2 SUDOC|031193722‏
996 ‎‡2 ISNI|000000011322938X‏
996 ‎‡2 BNE|XX1470669‏
996 ‎‡2 ISNI|0000000116962990‏
996 ‎‡2 J9U|987007315745105171‏
996 ‎‡2 DNB|1261861949‏
996 ‎‡2 ISNI|0000000369786120‏
996 ‎‡2 BNE|XX1085998‏
996 ‎‡2 BNE|XX1461446‏
996 ‎‡2 BNE|XX930246‏
996 ‎‡2 SUDOC|229942113‏
996 ‎‡2 ISNI|0000000138748899‏
996 ‎‡2 NUKAT|n 2008150252‏
996 ‎‡2 BNE|XX947712‏
996 ‎‡2 LC|no2023004964‏
996 ‎‡2 ISNI|0000000500039279‏
996 ‎‡2 LC|no2006045675‏
996 ‎‡2 NYNYRILM|393332‏
996 ‎‡2 BNE|XX1266130‏
996 ‎‡2 RERO|A003822991‏
996 ‎‡2 BNE|XX979855‏
996 ‎‡2 RERO|A023981877‏
996 ‎‡2 PTBNP|78605‏
996 ‎‡2 DNB|129967335‏
996 ‎‡2 ISNI|0000000059525603‏
996 ‎‡2 SZ|171834054‏
996 ‎‡2 LC|nb2011020220‏
996 ‎‡2 ISNI|0000000034929169‏
996 ‎‡2 PTBNP|236522‏
996 ‎‡2 LC|n 2001036574‏
996 ‎‡2 NSK|000245137‏
996 ‎‡2 SUDOC|250681870‏
996 ‎‡2 ISNI|0000000115732704‏
996 ‎‡2 DNB|1056622725‏
996 ‎‡2 BNE|XX1617858‏
996 ‎‡2 BNE|XX5452055‏
996 ‎‡2 BNE|XX1044006‏
996 ‎‡2 SUDOC|185130550‏
996 ‎‡2 BNE|XX992353‏
996 ‎‡2 SUDOC|052532909‏
996 ‎‡2 DNB|1025705386‏
996 ‎‡2 DNB|1057115916‏
996 ‎‡2 BNE|XX4896738‏
996 ‎‡2 CAOONL|ncf10619152‏
996 ‎‡2 ISNI|0000000059972702‏
996 ‎‡2 LC|no2002084669‏
996 ‎‡2 BNF|13750687‏
996 ‎‡2 ISNI|0000000502817302‏
996 ‎‡2 BNE|XX913499‏
996 ‎‡2 BNCHL|10000000000000000024314‏
996 ‎‡2 JPG|500003768‏
996 ‎‡2 PTBNP|1185780‏
996 ‎‡2 ISNI|0000000109038855‏
996 ‎‡2 BNE|XX900235‏
996 ‎‡2 RERO|A022262974‏
996 ‎‡2 PTBNP|1584696‏
996 ‎‡2 DNB|129464732‏
996 ‎‡2 DNB|171893166‏
996 ‎‡2 LC|no2012057726‏
996 ‎‡2 BNC|981058523566806706‏
996 ‎‡2 ISNI|0000000118736321‏
996 ‎‡2 BNCHL|10000000000000000009565‏
996 ‎‡2 ISNI|0000000119047907‏
996 ‎‡2 SUDOC|253992206‏
996 ‎‡2 SUDOC|069811253‏
996 ‎‡2 ISNI|0000000115754161‏
996 ‎‡2 ISNI|000000004884828X‏
996 ‎‡2 BNE|XX1554339‏
996 ‎‡2 BNE|XX6094744‏
996 ‎‡2 PTBNP|1609772‏
996 ‎‡2 BNE|XX1038381‏
996 ‎‡2 BNE|XX5129849‏
996 ‎‡2 SUDOC|189490942‏
996 ‎‡2 BNE|XX1646039‏
996 ‎‡2 NTA|314069704‏
996 ‎‡2 ISNI|0000000061025448‏
996 ‎‡2 DNB|141517263‏
996 ‎‡2 LC|nb 99128031‏
996 ‎‡2 LC|n 2007072265‏
996 ‎‡2 DNB|1057436631‏
996 ‎‡2 PTBNP|1711587‏
996 ‎‡2 BNE|XX824179‏
996 ‎‡2 DNB|105647808X‏
996 ‎‡2 BNC|981058513630106706‏
996 ‎‡2 PTBNP|216734‏
996 ‎‡2 PTBNP|1629625‏
996 ‎‡2 NUKAT|n 2005008467‏
996 ‎‡2 NTA|069545286‏
996 ‎‡2 RERO|A006481039‏
996 ‎‡2 ISNI|000000039930759X‏
996 ‎‡2 DNB|1059931370‏
996 ‎‡2 BNE|XX5469023‏
996 ‎‡2 LC|n 2010037378‏
996 ‎‡2 LC|no2017116271‏
996 ‎‡2 ISNI|0000000059761163‏
996 ‎‡2 BNCHL|10000000000000000169874‏
996 ‎‡2 ISNI|0000000059216157‏
996 ‎‡2 BNC|981058515172106706‏
996 ‎‡2 DNB|1250428769‏
996 ‎‡2 ISNI|0000000068502243‏
996 ‎‡2 ISNI|0000000108158978‏
996 ‎‡2 BNE|XX1366861‏
996 ‎‡2 BNE|XX5525752‏
996 ‎‡2 BNE|XX6181772‏
996 ‎‡2 SUDOC|191888591‏
996 ‎‡2 BNC|981060555933106706‏
996 ‎‡2 RERO|A003227668‏
996 ‎‡2 ISNI|0000000116466786‏
996 ‎‡2 ISNI|0000000448737327‏
996 ‎‡2 PTBNP|1262132‏
996 ‎‡2 ISNI|0000000059539650‏
996 ‎‡2 LC|n 97075963‏
996 ‎‡2 ISNI|0000000079716693‏
996 ‎‡2 BNE|XX1068355‏
996 ‎‡2 SUDOC|176331174‏
996 ‎‡2 B2Q|0001096483‏
996 ‎‡2 LC|n 80098391‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏
998 ‎‡a Serrano, María Concepción‏ ‎‡2 LC|n 2022183985‏ ‎‡3 title: (0.73, 'engineeringbiomaterialsforneuralapplications', 'naturallyderivedbiomaterialsfortissueengineeringapplications')‏